Sort by
Keyphrases
Epidermal Growth Factor Receptor
100%
Colorectal Cancer
100%
Vitamin C
100%
Acquired Resistance
100%
Receptor-targeted Therapy
100%
Cetuximab
83%
Oxidative Stress
50%
Colorectal Cancer Patients
50%
In Cancer
16%
Cancer Types
16%
Proteomics
16%
Iron Homeostasis
16%
Cancer Patients
16%
ROS Production
16%
Metabolic
16%
Glucose Uptake
16%
Glycolysis
16%
Initial Treatment
16%
Multidrug-resistant
16%
Receptor Blockade
16%
Long-term Efficacy
16%
Clinical Impact
16%
Pharmacological Dose
16%
Secondary Resistance
16%
Cell Death Program
16%
Targeted Agents
16%
Ferroptosis
16%
Antioxidant Agents
16%
Cell Metabolism
16%
Carbohydrate Metabolism
16%
Receptor Targets
16%
ATP Depletion
16%
Anti-epidermal Growth Factor Receptor Therapy
16%
Advanced Colorectal Cancer
16%
Targeting Antibodies
16%
Patient-derived Xenograft
16%
BRAF Wild Type
16%
ROS Level
16%
Anti-epidermal Growth Factor Receptor Antibody
16%
Metabolic Flux Analysis
16%
High Dose Vitamin C
16%
Cancer Organoids
16%
Synthetic Lethal
16%
Persister Cells
16%
Persisters
16%
Medicine and Dentistry
Targeted Therapy
100%
Colorectal Carcinoma
100%
Epidermal Growth Factor Receptor
100%
Ascorbic Acid
100%
Cetuximab
83%
Oxidative Stress
50%
Reactive Oxygen Species
33%
Anti-Epidermal Growth Factor Receptor
33%
Cancer Types
16%
Malignant Neoplasm
16%
Drug Megadose
16%
Adenosine Triphosphate
16%
Iron Homeostasis
16%
Receptor Blocking
16%
Cell Death
16%
Glucose Uptake
16%
Antioxidant
16%
Xenograft
16%
Ferroptosis
16%
Carbohydrate Metabolism
16%
Cell Metabolism
16%
Organoid
16%
Epidermal Growth Factor Receptor Antibody
16%
Metabolic Flux Analysis
16%
Proteomics
16%